Navigation Links
Hospira Names Brian Meadows Supply Chain Chief
Date:4/27/2009

LAKE FOREST, Ill., April 27 /PRNewswire-FirstCall/ -- Hospira, Inc. (NYSE: HSP), a global specialty pharmaceutical and medication delivery company, announced today that Brian Meadows has been named corporate vice president, Supply Chain. In this capacity, he will be responsible for enterprise-wide supply chain operations including demand and supply planning; strategic sourcing and supplier management; procurement; materials and production planning; transportation management and distribution operations.

In addition, Meadows will lead the procurement effort within Project Fuel, Hospira's multi-phased initiative designed to identify and liberate resources across the organization to reduce complexity, improve efficiencies and optimize financial performance. The procurement effort will leverage Hospira's global scale to provide a sustainable advantage in the areas of productivity, cost, innovation and flexibility with the company's suppliers.

"Brian is a proven operations executive with leadership strengths in supply chain management and cost reduction," said Terrence C. Kearney, chief operating officer, Hospira. "Establishing Hospira's supply chain as a competitive advantage is a key strategic imperative, and we're excited to have Brian leading this effort."

Most recently, Meadows, 48, was senior vice president of supply chain management at Sprint-Nextel Corporation, where he led the integration of the supply chain operations of Sprint and Nextel Communications. Prior to Sprint, Meadows was the senior vice president of supply chain management at Nextel, where he centralized and built the supply chain organization. His supply chain operating experience is complemented by a consulting career in which he was a principal at A.T. Kearney and a partner at Deloitte Consulting.

Meadows earned his bachelor's degree from the University of Wisconsin-Madison in Civil and Environmental Engineering, and his master's of business management from the Kellogg School of Management at Northwestern University.

About Hospira

Hospira, Inc. is a global specialty pharmaceutical and medication delivery company dedicated to Advancing Wellness(TM). As the world leader in specialty generic injectable pharmaceuticals, Hospira offers one of the broadest portfolios of generic acute-care and oncology injectables, as well as integrated infusion therapy and medication management solutions. Through its products, Hospira helps improve the safety, cost and productivity of patient care. The company is headquartered in Lake Forest, Ill., and has more than 14,000 employees. Learn more at www.hospira.com.


'/>"/>
SOURCE Hospira, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Biogenerics Will Save Billions, Says Hospira CEO
2. Hospiras Biosimilar Epoetin Retacrit(TM) Receives Positive Opinion Recommending EU Approval
3. Hospira Expands Board of Directors
4. Human Genome Sciences Announces Process Development and Manufacturing Alliance With Hospira
5. Hospira Hosts Conference Call for Third-Quarter 2008 Earnings
6. StemCor Signs Agreement With Hospira to Market New Medical Device to Oncologists and Hematologists
7. Hospira Advances Patient Safety With New GemStar(R) SP Infusion System
8. Hospira Supports Newly Introduced Biogenerics Legislation
9. KGI Names Kerry Howell Vice President for Advancement
10. Vical Names Andrew de Guttadauro Vice President, Corporate Development
11. IDM Pharma Names Dr. Jeffrey W. Sherman Chief Medical Officer and Senior Vice President of Research and Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... ... April 29, 2016 , ... Summit for Stem Cell has received a $250,000 ... patient-specific stem cell therapy for the treatment of Parkinson’s disease. The Summit research project ... The Scripps Research Institute in San Diego, CA. , The aim of ...
(Date:4/28/2016)... , ... April 28, 2016 , ... ... ongoing support for Connecticut's innovative, growing companies, today announced the launch of ... financial technology (fintech) companies. , “VentureClash looks to attract the best ...
(Date:4/27/2016)... ... 27, 2016 , ... Shimadzu Scientific Instruments (SSI) will be ... Business Conference and Expo. Shimadzu’s high-performance instruments enable laboratories to test cannabis products ... can stop by booth 1021 to learn how Shimadzu’s instruments can help improve ...
(Date:4/27/2016)... ... 27, 2016 , ... The Board of Directors of Biohaven ... Tilton as Chief Commercial Officer.  Mr. Tilton joined Biohaven from Alexion Pharmaceuticals, Inc. ... responsible for the commercialization of multiple orphan drug indications. Mr. Tilton has ...
Breaking Biology Technology:
(Date:3/11/2016)... , March 11, 2016 ... new market research report "Image Recognition Market by Technology ... (Marketing and Advertising), by Deployment Type (On-Premises and Cloud), ... To 2022", published by MarketsandMarkets, the global market is ... to USD 29.98 Billion by 2020, at a CAGR ...
(Date:3/9/2016)... March 9, 2016 This BCC Research report ... of the RNA Sequencing (RNA Seq) market for the ... instruments, tools and reagents, data analysis, and services. ... of the RNA-Sequencing market such as RNA-Sequencing tools and ... main factors affecting each segment and forecast their market ...
(Date:3/8/2016)... 8, 2016   Valencell , the leading ... it has secured $11M in Series D financing. ... new venture fund being launched by UAE-based financial ... existing investors TDF Ventures and WSJ Joshua Fund. ... its triple-digit growth and accelerate its pioneering innovation ...
Breaking Biology News(10 mins):